Prognose

Køb	4
Behold	0
Sælg	0

Nyheder Til nyhedsfeedet

GENFIT: Phase‑1 shows favorable safety profile and strong anti‑inflammatory effect of G1090N

GENFIT reports that the drug candidate G1090N showed a favorable safety profile in a Phase‑1 study of 76 healthy volunteers and, in ex‑vivo tests, strong inhibition of pro‑inflammatory signaling pathways (up to 76% reduction in LPS‑induced cytokines). The data support progression to further clinical trials; GENFIT plans discussions with regulators, including the FDA, to prepare Phase‑2 proof‑of‑concept studies for ACLF and related indications. The stock trades near its 52‑week high after rising more than 55% over the past six months. » Mere på de.investing.com
Genfit appoints Dr. Pejvack Motlagh as new chief medical officer

Genfit appoints Dr. Pejvack Motlagh effective immediately as chief medical officer; he brings more than 20 years of experience in pharma and biotech and will, as a member of the Executive Committee, lead the clinical development strategy as well as the clinical, biometrics and pharmacovigilance teams. The announcement comes against the backdrop of strong stock price momentum. In parallel, Genfit halted treatment with VS-01 for acute-on-chronic liver failure after a safety incident and will concentrate resources on the VS-01 program for urea cycle disorders. The company recently received accelerated approvals for Iqirvo (Elafibranor) in the US, Europe and the UK. » Mere på de.investing.com
Genfit halts VS-01 program for ACLF after safety incident – shares fall

Genfit reports discontinuation of the VS-01 treatment for acute-on-chronic liver failure (ACLF) following a case of peritonitis during the UNVEIL-IT study and a review by an independent data monitoring committee. The shares fell about 9% as a result. The company now plans to redirect VS-01 to urea cycle disorders (UCD); near-term catalysts are safety and early efficacy data for G1090N and Phase Ib data for GNS561 in cholangiocarcinoma by the end of 2025. Analysts note that VS-01 was not previously included in their valuation models but still view the stock as overall undervalued. » Mere på de.investing.com

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2022 har Genfit allerede udloddet 0,014 € i udbytte. Den seneste udlodning fandt sted i maj 2022.

Virksomhedstal

I det seneste kvartal havde Genfit en omsætning på 31,93 mio. € og et nettoresultat på -75,98 mio. €

(EUR)	december 2025	YoY
Omsætning	31,93 mio.	-
Bruttofortjeneste	-17,97 mio.	-
Nettoresultat	-75,98 mio.	-
EBITDA	-7,01 mio.	-

Fundamentale data

Nøgletal	Værdi
Markedsværdi	684,08 mio. €
Antal aktier	50,1 mio.
Højeste/laveste i 52 uger	14,31 € - 3,23 €
Udbytte	Nej
Beta	1,14
P/E (PE Ratio)	-7,57
PEG (PEG Ratio)	-0,02
K/I (PB Ratio)	-27,45
P/S (PS Ratio)	9,66

Virksomhedsprofil

Genfit S.A., ein biopharmazeutisches Unternehmen, erforscht und entwickelt Arzneimittelkandidaten und diagnostische Lösungen für Stoffwechsel- und Leberkrankheiten. Zu den Produkten des Unternehmens gehört Elafibranor, das sich in einer klinischen Studie der Phase 3 zur Behandlung von Patienten mit primärer biliärer Cholangitis befindet. Darüber hinaus entwickelt das Unternehmen die NIS4-Technologie zur Diagnose von nichtalkoholischer Steatohepatitis (NASH) und Fibrose, GNS561, das sich in einer Phase-1b/2-Studie zur Behandlung von Patienten mit Cholangiokarzinom (CCA) befindet, und Nitazoxanid, das sich in einer Phase-1-Studie zur Behandlung von akut-chronischem Leberversagen befindet. Das Unternehmen hat eine Lizenzvereinbarung mit Labcorp zur Vermarktung von NASHnext, einem blutbasierten molekularen Diagnosetest, und mit Genoscience Pharma zur Entwicklung und Vermarktung des Prüfpräparats GNS561 für CCA. Genfit S.A. wurde 1999 gegründet und hat seinen Hauptsitz in Loos, Frankreich.